Faron Pharmaceuticals Oy Share Discussion Threads

[11_percent] 02/5/2018 10:44

Chrysalis99
2 May '18 - 10:09 - 81 of 82
0 0 0
Analysts' views don't fill me with confidence, but the preparations for commercial launch already being put in place by Faron do.
-------------

I would go with that.

Already setting up manufacturing.......and advertising for the marketing/business guys for the US.

[11_percent] 02/5/2018 10:43

waterloo01
2 May '18 - 10:03 - 80 of 81
0 0 0
In what way are the 'results known'?

===========

The results of the trials are now know, this is fact. The report, etc, may not be written but the result will be know.

Someone will be trading on this information, and it is naïve to think its not happening.

It is a matter of trying to find the extent.

[chrysalis99] 02/5/2018 10:09

Analysts' views don't fill me with confidence, but the preparations for commercial launch already being put in place by Faron do.

[waterloo01] 02/5/2018 10:03

In what way are the 'results known'?

[11_percent] 02/5/2018 09:50

There seems to be an overhang of shares from the placing, which is stopping any rise.

It is not unusual for a thin traded share to be taken lower before results. the results of the trial will be known, and my guess is they are good.

It is just a matter of how low this will go before the RNS, and then it should fly.

Anyway, I am buying at these levels.

[waterloo01] 02/5/2018 08:26

Chysalis, no idea just brief feedback from an institutional sector specialist.

Immy, yes looks much more robust but as with all biotech, not nailed on until it reports. Seeing they raised at £8.00 seems like a reasonable price but won't get over exposed (holdings wise).

[immy1992] 02/5/2018 08:19

Hi Waterloo good to see you here. I took a small position at 814 yesterday after doing a bit of research.

Learning from IMM their p2 six month data showed had p values of about 0.3-0.4 can't remember correctly. So obviously first thing I did was look at p2 data closely

I looked at the p2 Lancet paper and saw that even with a small group of 37 vs 59 they achieved at 81 percent reduction in mortality and reduction in ICU days from 28 to 16. P value 0.01. I like these odds very much, plus they also identified an optimal dosing so I guess even nobby would be happy ?. Their eu p3 trial looks powered enough and their end points being 50 percent reduction leaves a fair bit of wiggle room. Plus it also does not say how many days reduction in icu they are targeting so I guess even targeting so I guess 1 or 2 days would cut it ?

Read and rns saying they'd be providing day 90 mortality rate as well, no hard data from lancet paper but it was mentioned that their secondary endpoints showed improvement in standard of life over time too. That's the only grey for me right now

The chart looks very steady too minus the don't Dong trading since jan. Should have waited till days end could have got in cheaper but oh well.

Its awfully quiet on both lse and advfn though! Surprisingly no broker targets or share price forecasts. I guess we've stumbled upon another spa blockbuster potential , interesting to see what happens

[chrysalis99] 02/5/2018 08:13

On what reasoning Waterloo01?

[waterloo01] 02/5/2018 07:23

Had some feedback from event they presented at in Monaco last month. The analyst thought IMM would fail (it did) but FARN trial would succeed.

[immy1992] 02/5/2018 06:23

Wow this BB is awfully quiet for a company with so much potential. Phase 2 data 80 percent reduction in mortality rate p=0.01 reduction in stay in ICU from 28 to 16 days

Phase 3 targeting 50 percent reduction in mortality rate and reduction in stay in ICU ( days not specified) . If eu phase 3 successful then straight to MAA. FDA allowed them to skip p3 America and file for BLA based on successful EU and Japan p3. Eu results due soon .

Am I missing something here or is this just looking very very good ?

[11_percent] 30/4/2018 08:33

The boys are piling in now.....

[11_percent] 30/4/2018 08:27

Yesss...........every trade a buy (except the "UT")......and the share price moved...

[11_percent] 30/4/2018 08:04

We did .....but did not move the price...

[11_percent] 30/4/2018 07:55

Will be interesting to see if we get a flurry of small trades/buys at the start.

[papillon] 29/4/2018 23:02

............

[chrysalis99] 29/4/2018 17:57

Perhaps outcome will coincide with annual results on 8th May.

[11_percent] 29/4/2018 09:38

That would fit with the 18th April date.

[waterloo01] 29/4/2018 09:29

Small piece in Sunday Times on Faron suggesting results out in a few weeks.

[arcadian] 25/4/2018 13:09

I asked them about the large trades yesterday and they have just put out an RNS showing Polar Capital increased their holding by c.150000 yesterday.

PS the big trades were all shown as sells on Advfn but turned out that at least 150000 were purchases by Pokar. . Did the same happen today with the clusters of 20k trades?

[arcadian] 13/4/2018 18:32

They do seem to be oozing confidence as they boldly plan ahead re manufacture and distribution etc. They do seem to be sure of a positive outcome. Given the fast track I assume that the FDA will accept the results of the phase 3 trials in Japan and Europe. Roll on May 8th



.

[allonblack] 13/4/2018 15:13

Just a heads up. I spotted that Faron has just today put two new jobs on its web site. Head of US Pricing and Market Access and Head of US Market Analysis and Intelligence. Clearly still confident about the results.

[arcadian] 10/4/2018 10:53

Paxman

Thanks for that. I missed it. Stocks discussions seem to jump around.

Have to ask you. Any Nottinghamshire connections? If not please ignore.

[paxman] 06/4/2018 11:11

Breq from over at Stocko attended. She said:

Some interesting things not obvious from the presentation. Company estimates trial results by May 8. That's the date final 2017 results are announced. Obviously just a target as we all know trial results can be delayed.

Mention of further share price gains possible soon. Said in a controlled but positive way. i.e. company still optimistic on trial results.

100,000 treatments available by mid 2019 because company expects demand to be that high.
How could doctors not use Traumakine if effective?

Breq scanned the Faron website/Linkedin etc. New appointments with a focus on delivering Traumakine so Faron still confident.